Home›Stock Screener›Indo Us Bio-Tech›Financial Statements

Indo Us Bio-Tech Complete Financial Statements

3 Years of Data
2022 - 2020

In FYNone, Indo Us Bio-Tech (INDOUS) reported revenue ₹0 Cr, net profit ₹0 Cr and EPS ₹0.00, with a net profit margin of 10.0% and ROE of 12.8%. Full financial statements from FY2020 to FY2022 (3 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Indo Us Bio-Tech share price screener.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 10.00% 2022 data
EBITDA Margin 14.00% 2022 data
Operating Margin 14.00% 2022 data
Return on Assets 8.93% 2022 data
Return on Equity 12.82% 2022 data

Balance Sheet Ratios

Current Ratio 9.40 2022 data
Equity Ratio 69.64% 2022 data
Asset Turnover 0.89 2022 data

INDOUS Revenue, Net Profit & EBITDA — Year-on-Year Growth

INDOUS YoY (March 2022 vs Period) — revenue -100.0%, net profit -100.0%, EBITDA -100.0%, expenses -100.0%. Review INDOUS earnings multiple to evaluate earnings-based valuation against sector peers.

Revenue Growth
-100.0%
Year-over-Year
Net Profit Growth
-100.0%
Year-over-Year
EBITDA Growth
-100.0%
Year-over-Year
Expense Growth
-100.0%
Year-over-Year
Assets Growth
+27.3%
Year-over-Year
Equity Growth
+85.7%
Year-over-Year
Investing Cash Flow Growth
-150.0%
Year-over-Year
Financing Cash Flow Growth
+50.0%
Year-over-Year

INDOUS Income Statement — Revenue, EBITDA & Net Profit

Indo Us Bio-Tech revenue ₹0 Cr, EBITDA ₹0 Cr, net profit ₹0 Cr, EPS ₹0.00 (None) — net profit margin 10.0%. Explore Indo Us Bio-Tech intrinsic price to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars None March 2022 March 2021 March 2020
Revenue 0 50 40 40
Expenses 0 43 35 36
EBITDA 0 7 5 4
Operating Profit Margin % 0.00% 14.00% 13.00% 10.00%
Depreciation 0 1 0 0
Interest 0 1 1 1
Profit Before Tax 0 5 4 3
Tax 0 0 -1 0
Net Profit 0 5 5 3
Earnings Per Share (₹) 0.00 8.27 8.07 4.18

INDOUS Balance Sheet — Assets, Liabilities & Shareholders' Equity

INDOUS total assets ₹56 Cr, total equity ₹39 Cr, total liabilities ₹ Cr (2022) — ROE 12.8%.

Years Annual Data ₹ Crores
Particulars 2022 2021 2020
ASSETS
Total Assets 56 44 35
Current Assets 47 38 32
Fixed Assets 6 2 1
Capital Work in Progress 2 2 1
Investments 0 0 0
Other Assets 48 39 32
LIABILITIES
Total Liabilities
Current Liabilities 5 4 2
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 39 21 16
Share Capital 9 6 6
Reserves & Surplus 29 15 10

INDOUS Cash Flow Statement — Operating, Investing & Financing

Indo Us Bio-Tech operating cash flow ₹3 Cr, investing ₹-5 Cr, financing ₹3 Cr, net cash flow ₹0 Cr (2022).

Periods ₹ Crores
Particulars March 2022 March 2021 March 2020
Operating Activities 3 0 -1
Investing Activities -5 -2 -1
Financing Activities 3 2 2
Net Cash Flow 0 0 0